Intuitive Surgical (NASDAQ:ISRG) EVP Sells $51,864.75 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet sold 105 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $493.95, for a total value of $51,864.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Myriam Curet also recently made the following trade(s):

• On Wednesday, February 11th, Myriam Curet sold 421 shares of Intuitive Surgical stock. The stock was sold at an average price of $494.96, for a total value of $208,378.16.
• On Tuesday, February 10th, Myriam Curet sold 105 shares of Intuitive Surgical stock. The stock was sold at an average price of $494.65, for a total value of $51,938.25.
• On Thursday, January 29th, Myriam Curet sold 126 shares of Intuitive Surgical stock. The shares were sold at an average price of $520.02, for a total value of $65,522.52.
• On Tuesday, January 27th, Myriam Curet sold 230 shares of Intuitive Surgical stock. The shares were sold at an average price of $532.61, for a total value of $122,500.30.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $472.16 on Friday. The business has a 50-day simple moving average of $513.26 and a 200-day simple moving average of $512.40. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $603.88. The company has a market cap of $167.68 billion, a PE ratio of 59.84, a P/E/G ratio of 3.70 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. During the same quarter last year, the company earned $2.21 earnings per share. The firm’s revenue was up 18.8% compared to the same quarter last year. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new stake in Intuitive Surgical in the fourth quarter valued at $2,856,987,000. J. Stern & Co. LLP grew its holdings in shares of Intuitive Surgical by 18,504.6% during the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after purchasing an additional 2,115,814 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Intuitive Surgical by 1,043.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock worth $760,124,000 after purchasing an additional 1,224,734 shares during the last quarter. Rakuten Investment Management Inc. acquired a new stake in shares of Intuitive Surgical during the third quarter worth about $388,436,000. Finally, Polen Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth about $477,225,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent analyst reports. Barclays set a $712.00 price objective on shares of Intuitive Surgical and gave the stock an “overweight” rating in a research report on Monday, January 26th. The Goldman Sachs Group reissued a “buy” rating and issued a $714.00 target price on shares of Intuitive Surgical in a report on Friday, January 9th. Royal Bank Of Canada lifted their price target on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Truist Financial upped their price objective on Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Robert W. Baird dropped their price objective on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $615.86.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.